Cochrane · systematic review · CD008440
Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women
Sturt, AS, Dokubo, EK, Sint, TT · Cochrane Database of Systematic Reviews · 2010 · Cochrane Library
HIV/AIDSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
47
current version
GRADE rated
46
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 2.1%Very low 28 · 59.6%Low 17 · 36.2%Moderate 1 · 2.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Kesho Bora: AZT/3TC/LPV‐r compared to Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) for HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Population: HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Infant HIV Transmission or Death at 6 Months Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) | RR 0.66 [0.43, 1] | 1 study · 795 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Infant HIV Transmission or Death at 12 months Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) | RR 0.64 [0.44, 0.92] | 1 study · 765 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Infant Mortality at 6 Months Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) | RR 0.78 [0.43, 1.42] | 1 study · 781 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Infant Mortality at 12 months Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) | RR 0.63 [0.38, 1.03] | 1 study · 751 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Maternal Grade 3/4 Severe Adverse Events Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) | RR 1.09 [0.77, 1.53] | 1 study · 824 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Infant Grade 3/4 Severe Adverse Events Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) | RR 0.95 [0.77, 1.16] | 1 study · 805 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Prematurity Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) | RR 1.23 [0.85, 1.79] | 1 study · 805 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Kesho Bora continued: AZT/3TC/LPV‐r compared to Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) for HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3 (second part of the preceding Summary of Findings table, showing additional outcomes)
Population: HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Low Birth Weight Kesho Bora continued: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) | RR 1.46 [0.94, 2.25] | 1 study · 805 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Stillbirths Kesho Bora continued: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) | RR 1 [0.25, 3.95] | 1 study · 824 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mother to Child Transmission at Birth Kesho Bora continued: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) | RR 0.78 [0.29, 2.07] | 1 study · 805 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mother to Child Transmission at 6 Weeks Kesho Bora continued: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) | RR 0.69 [0.34, 1.37] | 1 study · 789 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mother to Child Transmission at 6 Months Kesho Bora continued: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) | RR 0.56 [0.33, 0.99] | 1 study · 776 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mother to Child Transmission at 12 Months Kesho Bora continued: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) | RR 0.58 [0.34, 0.97] | 1 study · 761 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Lehman: AZT/3TC/NVP compared to Short Course AZT/sdNVP for HIV‐Infected Pregnant Women With CD4 Counts 200‐500 cells/mm3
Population: HIV‐Infected Pregnant Women With CD4 Counts 200‐500 cells/mm3
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Maternal Resistance Lehman: AZT/3TC/NVP vs Short Course AZT/sdNVP | RR 0.24 [0.07, 0.88] | 1 study · 27 participants | Very low Downgraded: risk of bias, imprecision |
Mma Bana: AZT/3TC/LPV‐r compared to AZT/3TC/ABC for HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3
Population: HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Infant Mortality at 6 Months Mma Bana: AZT/3TC/LPV‐r vs AZT/3TC/ABC | RR 0.95 [0.34, 2.68] | 1 study · 553 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Women With Any Grade 3/4 Severe Adverse Event (Laboratory Only) Mma Bana: AZT/3TC/LPV‐r vs AZT/3TC/ABC | RR 0.79 [0.51, 1.21] | 1 study · 560 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Women With Any Severe Adverse Events Requiring Treatment Modification Mma Bana: AZT/3TC/LPV‐r vs AZT/3TC/ABC | RR 0.89 [0.3, 2.61] | 1 study · 560 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Infants With Any Grade 3/4 Severe Adverse Events Mma Bana: AZT/3TC/LPV‐r vs AZT/3TC/ABC | RR 1.13 [0.93, 1.37] | 1 study · 553 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Prematurity Mma Bana: AZT/3TC/LPV‐r vs AZT/3TC/ABC | RR 1.52 [1.07, 2.17] | 1 study · 553 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Infant Low Birth Weight Mma Bana: AZT/3TC/LPV‐r vs AZT/3TC/ABC | RR 1.27 [0.85, 1.91] | 1 study · 553 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mma Bana continued: AZT/3TC/LPV‐r compared to AZT/3TC/ABC for HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3 (second part of the preceding Summary of Findings table, showing additional outcomes)
Population: HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Stillbirths Mma Bana continued: AZT/3TC/LPV‐r vs AZT/3TC/ABC | RR 0.65 [0.21, 1.96] | 1 study · 560 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Maternal Mortality at Six Months Mma Bana continued: AZT/3TC/LPV‐r vs AZT/3TC/ABC | RR 0.35 [0.01, 8.44] | 1 study · 560 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mother to Child Transmission In Utero Positive HIV DNA PCR Within 96 Hours Mma Bana continued: AZT/3TC/LPV‐r vs AZT/3TC/ABC | RR 0.35 [0.04, 3.34] | 1 study · 553 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mother to Child Transmission Late Postpartum Negative HIV DNA PCR at Birth and One Month, But Positive HIV DNA PCR at Six Months Mma Bana continued: AZT/3TC/LPV‐r vs AZT/3TC/ABC | RR 0.21 [0.01, 4.35] | 1 study · 553 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Mother to Child Transmission at Six Months Post‐Partum All Positive HIV DNA PCRs at Six Months Mma Bana continued: AZT/3TC/LPV‐r vs AZT/3TC/ABC | RR 0.17 [0.02, 1.44] | 1 study · 553 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Bae: AZT/3TC/NVP vs. AZT (+/‐ single dose NVP) for HIV‐infected pregnant women with CD4 Counts <200 cells/mm3
Population: HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV‐Transmission or Death at 7 Months Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) | RR 0.39 [0.18, 0.85] | 1 study · 178 participants | Very low Downgraded: imprecision |
Infant Grade 3/4 Severe Adverse Events at Birth Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) | RR 1.26 [0.35, 4.54] | 1 study · 178 participants | Very low Downgraded: imprecision |
Prematurity Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) | RR 0.56 [0.21, 1.5] | 1 study · 178 participants | Very low Downgraded: imprecision |
Mother to Child Transmission at Birth Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) | RR 0.18 [0.02, 1.36] | 1 study · 178 participants | Very low Downgraded: imprecision |
Mother to Child Transmission at 1 Month Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) | RR 0.23 [0.05, 0.96] | 1 study · 178 participants | Very low Downgraded: imprecision |
Mother to Child Transmission Cumulative by 7 Months Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP) | RR 0.15 [0.04, 0.62] | 1 study · 178 participants | Very low Downgraded: imprecision |
Ekouevi: AZT/3TC/NVP compared to Other Short Course PMTCT Regimen for ART‐Eligible HIV‐infected Pregnant Women
Population: ART‐Eligible HIV‐infected Pregnant Women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Stillbirths Ekouevi: AZT/3TC/NVP vs Other Short Course PMTCT Regimen | RR 1.16 [0.34, 3.93] | 1 study · 326 participants | Very low Downgraded: imprecision |
Infant Low Birth Weight Ekouevi: AZT/3TC/NVP vs Other Short Course PMTCT Regimen | RR 1.81 [1.09, 3] | 1 study · 309 participants | Very low Downgraded: imprecision |
Mother to Child Transmission at 12 Months Ekouevi: AZT/3TC/NVP vs Other Short Course PMTCT Regimen | RR 0.14 [0.04, 0.47] | 1 study · 311 participants | Very low Downgraded: imprecision |
Jamisse (What to Start): AZT/3TC/NVP compared to d4T/3TC/NVP for HIV‐Infected Pregnant Women With CD4<350
Population: HIV‐Infected Pregnant Women With CD4<350
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Maternal Grade 3/4 Severe Adverse Events Jamisse (What to Start): AZT/3TC/NVP vs d4T/3TC/NVP | RR 1.58 [0.6, 4.12] | 1 study · 146 participants | Very low Downgraded: imprecision |
Jamisse (When to Start): AZT/3TC/NVP for CD4 250‐350 compared to AZT/3TC/NVP for CD4 <250 for HIV‐Infected Pregnant Women
Population: HIV‐Infected Pregnant Women1
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Maternal Grade 3/4 Severe Adverse Events Jamisse (When to Start): AZT/3TC/NVP for CD4 250‐350 vs AZT/3TC/NVP | RR 1.18 [0.47, 2.97] | 1 study · 146 participants | Very low Downgraded: imprecision |
Marazzi: AZT/3TC/NVP for HIV Infection in Pregnant Women With CD4 <250 vs. >250 cells/mm3
Population: HIV‐infected Pregnant Women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Maternal Grade 3/4 Hepatotoxicity Marazzi: AZT/3TC/NVP for HIV Infection in Pregnant Women With CD4 <250 vs >250 cells/mm3 | RR 0.64 [0.34, 1.2] | 1 study · 703 participants | Ungraded |
Phanuphak: AZT/3TC/NVP (PMTCT) compared to AZT/3TC/NVP (ART) for HIV‐1 Infected Pregnant Women Who Have CD4>200 Compared with Those Who Have CD4<200 Cells/mm3
Population: HIV‐1 Infected Pregnant Women Who Have CD4>200 Compared with Those Who Have CD4<200 Cells/mm3
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Maternal Grade 3/4 Severe Adverse Events Phanuphak: AZT/3TC/NVP (PMTCT) vs AZT/3TC/NVP (ART) | RR 1.98 [0.65, 6.03] | 1 study · 244 participants | Very low Downgraded: imprecision |
Tonwe‐Gold: AZT/3TC/NVP compared to Other Short Course Regimen for HIV‐Infected Pregnant Women
Population: HIV‐Infected Pregnant Women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HIV Transmission or Death at 1 Month Tonwe‐Gold: AZT/3TC/NVP vs Other Short Course Regimen | RR 0.86 [0.25, 2.97] | 1 study · 218 participants | Very low Downgraded: imprecision, indirectness |
HIV Transmission or Death at 12 Months Tonwe‐Gold: AZT/3TC/NVP vs Other Short Course Regimen | RR 0.86 [0.42, 1.77] | 1 study · 189 participants | Very low Downgraded: imprecision, indirectness |
Infant Mortality at 1 Month Tonwe‐Gold: AZT/3TC/NVP vs Other Short Course Regimen | RR 1.33 [0.27, 6.47] | 1 study · 231 participants | Very low Downgraded: imprecision, indirectness |
Maternal Grade 3/4 Severe Adverse Events Requiring Treatment Modification Tonwe‐Gold: AZT/3TC/NVP vs Other Short Course Regimen | RR 25.33 [1.49, 430.51] | 1 study · 250 participants | Very low Downgraded: imprecision, indirectness |
Infant Low Birth Weight Tonwe‐Gold: AZT/3TC/NVP vs Other Short Course Regimen | RR 2.17 [1.23, 3.81] | 1 study · 231 participants | Very low Downgraded: imprecision, indirectness |
Tonwe‐Gold continued: AZT/3TC/NVP compared to Other Short Course Regimen for HIV‐Infected Pregnant Women (second part of the preceding Summary of Findings table, showing additional outcomes)
Population: HIV‐Infected Pregnant Women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Stillbirths Tonwe‐Gold continued: AZT/3TC/NVP vs Other Short Course Regimen | RR 0.89 [0.26, 3.08] | 1 study · 241 participants | Very low Downgraded: imprecision, indirectness |
Maternal Mortality at Delivery Tonwe‐Gold continued: AZT/3TC/NVP vs Other Short Course Regimen | no estimate extracted | 1 study · 241 participants | Very low Downgraded: imprecision, indirectness |
Mother to Child Transmission of HIV at 1 Month Tonwe‐Gold continued: AZT/3TC/NVP vs Other Short Course Regimen | RR 0.32 [0.04, 2.83] | 1 study · 217 participants | Very low Downgraded: imprecision, indirectness |
Mother to Child Transmission of HIV at 12 Months Tonwe‐Gold continued: AZT/3TC/NVP vs Other Short Course Regimen | RR 0.4 [0.11, 1.41] | 1 study · 188 participants | Very low Downgraded: imprecision, indirectness |